SOLENO THERAPEUTICS INC 8-K

What Happened
Soleno Therapeutics (SLNO) reported on Form 8-K (filed April 7, 2026) that it has voluntarily withdrawn its marketing authorization application (MAA) for VIOKAT prolonged‑release tablets (diazoxide choline). VIOKAT is the company’s medicinal product for treating adults and children aged 4 years and older with Prader‑Willi syndrome (PWS) who experience hyperphagia; it is marketed in the U.S. as VYKAT™ XR. The application had been under review by the European Medicines Agency (EMA) with an expected decision in mid‑2026; Soleno says the withdrawal is based on business and strategic considerations and preserves the option to re‑engage with regulators later.

Key Details

• Form 8‑K filed: April 7, 2026.
• Product: VIOKAT (diazoxide choline) prolonged‑release tablets; U.S. brand name VYKAT XR.
• Indication: Treatment for PWS patients aged 4 years and older who experience hyperphagia.
• Reason given: Voluntary withdrawal for business and strategic reasons; preserves ability to re‑engage with EMA in future.

Why It Matters
For investors, withdrawing the MAA means Soleno’s path to a European approval (and potential EU commercialization and revenue) is paused or delayed; the company did not report financial impacts or alternative timelines in the filing. The action signals a strategic reassessment of the program rather than a regulatory denial, and Soleno retains the option to return to EMA if an appropriate pathway is identified. Investors should watch for further updates on regulatory strategy, potential commercialization plans, or financial guidance in future SEC filings and company announcements. The company also included standard forward‑looking statement language noting there is no assurance it will re‑engage with regulators.